Corvus Pharmaceuticals, Inc. (CRVS) earnings
CRVS earnings moved a median of 0.00% by the close. Quarterly and annual CRVS reports and results, each read against the price at its own news timestamp. Back to the CRVS overview →
27 measured CRVS earnings events.
Where these CRVS earnings landedvs 27 measured CRVS earnings reactions
| Middle 50% of CRVS earnings reactions | -3.03% to +4.90% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 27 |
Point-in-time · zero look-ahead
Half of the 27 CRVS earnings events with a measured close landed between -3.03% and +4.90%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results | Press release | +4.76% | +8.66% | |
| Form 10-Q Corvus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +4.76% | +8.66% | |
| Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 | Press release | -0.68% | +0.15% | |
| Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | +2.97% | +5.00% | |
| Form 10-Q Corvus Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +2.97% | +5.00% | |
| Form 10-K Corvus Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +2.73% | -1.42% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | +3.91% | -0.13% | |
| Form 10-Q Corvus Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +3.91% | -0.13% | |
| Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 | Press release | -0.90% | -0.78% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results | Press release | -1.19% | +2.86% | |
| Form 10-Q Corvus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -1.19% | +2.86% | |
| Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 | Press release | -0.49% | +0.00% | |
| Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results | Press release | -0.00% | +5.98% | |
| Form 10-Q Corvus Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.00% | +5.98% | |
| Form 10-K Corvus Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +4.50% | -16.25% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results | Press release | -1.21% | -10.94% | |
| Form 10-Q Corvus Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -1.21% | -10.94% | |
| Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 | Press release | -0.83% | -9.02% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results | Press release | +0.78% | +2.81% | |
| Form 10-Q Corvus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.78% | +2.81% | |
| Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024 | Press release | +0.00% | -3.02% | |
| Form 10-Q Corvus Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -1.34% | +4.81% | |
| Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | +2.76% | -7.18% | |
| Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 | Press release | -1.10% | +6.08% | |
| Form 10-K Corvus Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +1.56% | -3.65% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results | Press release | -4.24% | -3.03% | |
| Form 10-Q Corvus Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -4.24% | -3.03% |
Keep exploring
More CRVS: analyst actions → · SEC filings → · CRVS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Amarin Corporation plc - American Depositary Shares (AMRN) | 211 | +0.30% | 55% |
| BioRestorative Therapies, Inc. (BRTX) | 209 | -0.82% | 38% |
| Journey Medical Corporation (DERM) | 208 | 0.00% | 50% |
| Windtree Therapeutics, Inc. (WINT) | 207 | -1.40% | 27% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.